New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects
Next-generation maturation inhibitor BMS-955176 shows good antiviral activity in combination with atazanavir
Targets proliferate in HIV cure research
New drug holds out promise of long-term control or even cure of HIV
New British guidelines recommend treatment for everyone with HIV
Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks
We may need to combine many approaches to achieve a cure, delegates hear
HIV attachment inhibitor BMS-663068 safe and effective in phase 2b study
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation
